SILVER SPRING, MD--(Marketwire - Feb 22, 2013) - Nuvilex Inc., (OTCQB: NVLX) an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for research and medicine is pleased to announce that its Chief Operating Officer, Dr. Gerald Crabtree sat for an interview with Stock House Group, a research and content development investor relations firm.

The interview can be heard at

As part of Stock House Group's CEO interview series, Dr. Crabtree described Nuvilex's unique living cell encapsulation technology and the advantages that the technology has over other methods of cell encapsulation. He also described the technology as a "platform" upon which treatments for many serious diseases, including cancer, diabetes, and those that may be treatable using stem cells, may be built.

Dr. Crabtree covered such topics as the Company's completed mid-phase clinical trials for the treatment of advanced, inoperable, pancreatic cancer. In these trials, Nuvilex's living cell encapsulation technology was used together with the well-known anticancer drug, ifosfamide. Results showed that the median survival time and one-year survival rate were almost double that seen in historical data for Gemzar®, the only drug approved by the FDA as a single agent for the treatment of this disease. He said of the results, "I have been in the cancer business for 40 years, so I think I know a good thing when I see it. The mere fact that we got similar results in two totally independent studies is what intrigues me -- it's not a one-time thing."

He also discussed the pivotal late-stage clinical trials in pancreatic cancer the company is preparing for and spoke of the ramifications that a positive outcome may bring to Nuvilex. He emphasized that this trial will compare Nuvilex's pancreatic cancer treatment on a "head-to-head" basis with Gemzar®.

Dr. Crabtree talked about Nuvilex's new subsidiary, Medical Marijuana Sciences, Inc., and emphasized that the Company will be focused on developing treatments, based on cannabinoids from Cannabis, for the most deadly and difficult-to-treat forms of cancer.

After reviewing Nuvilex's live cell encapsulation technology, results from the company's Phase II cancer trials, its future late stage clinical trial, and its recent move into the medical marijuana sector, Stock House Group issued a comprehensive research report on Nuvilex. The report can be found at

About Nuvilex

Nuvilex, Inc. (OTCQB: NVLX) has been a provider of all-natural products for many years. The company has been expanded to increase its natural product-based footprint through medical marijuana studies. We are an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for research and medicine. New developments by our company and subsidiaries will be substantial as we have been working on many fronts to move us forward. Our company's offerings will ultimately include cancer, diabetes and other treatments using the Company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development.

About Stock House Group

Stock House Group is a full service Investment Relations firm specializing in Awareness, Research, and Content Development. The firm offers a platform that allows CEO's to tell their story through the press, Research Reports, and CEO Interviews. At the same time, Stock House Group is building a library of Research for Investors to use allowing them to get more informed on small cap stocks.

Safe Harbor Statement
This press release contains forward-looking statements described within the 1995 Private Securities Litigation Reform Act involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.

Contact Information:

Investor Relations Contact for Nuvilex

Marlin Molinaro
Marmel Communications, LLC
Ph: (702) 434-8692